Dr. Reddy's Laboratories Ltd. (RDY)
-NYSE | Prev Close: | 37.66 |
|---|
| Open: | N/A |
|---|
| Bid: | 34.41 x 200 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 38.50 |
|---|
| Beta: | 0.68 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 27.28 - 38.74 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 243,229 |
|---|
| Market Cap: | 6.40B |
|---|
| P/E (ttm): | 20.28 |
|---|
| EPS (ttm): | 1.86 |
|---|
| Div & Yield: | 0.23 (0.60%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Innovative Therapeutic Development for Duchenne Muscular Dystrophy Moves Niche Stocks Up 300% to 400%: An Expert Portfolio Manager Discusses Investing in Health CareWall Street Transcript(Thu, May 16)
- Dr. Reddy's Earnings Increase Y/YZacks(Wed, May 15)
- Dr. Reddy's Laboratories Beats on Both Top and Bottom Linesat Motley Fool(Wed, May 15)
- Dr. Reddy's Laboratories Management Discusses Q4 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 14)
- Emerging Markets Morning Roundup: India's Inflation Slows; Renren Surges on Earningsat Barrons.com(Tue, May 14)
- Futures Turn Higher on Tepper Remarksat CNBC(Tue, May 14)
- Dr. Reddy’s Q4 & FY13 Financial ResultsBusiness Wire(Tue, May 14)
- Earnings Miss at PerrigoZacks(Tue, May 7)
- Perrigo Likely to Report In Line EarningsZacks(Mon, May 6)
- Higher Success Rates than Small-Molecule Drugs for Antibodies: Antibodies Display More Predictable Pharmacology and More Predictable Toxicity ProfilesWall Street Transcript(Fri, May 3)
- Mylan Reports in line EarningsZacks(Fri, May 3)
- Dr. Reddy's to Release Q4 and Full Year FY13 Results on May 14, 2013Business Wire(Tue, Apr 30)
- Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Apr 26)
- 3 Things You Need to Know in the Wake of Abbott's Earningsat Motley Fool(Wed, Apr 17)
- Still Neutral on MylanZacks(Mon, Apr 15)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| RDY | 0.00% | 6.40B |
| NVO | 0.00% | 92.98B |
| TEVA | 0.00% | 34.24B |
| AGN | 0.00% | 29.20B |
| FRX | 0.00% | 10.11B |
Key Statistics
| Forward P/E (1 yr): | 16.03 |
|---|
| P/S (ttm): | 2.92 |
|---|
| Ex-Dividend Date: | 27-Jun-12 |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 2.05 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.40 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 1.28 |
|---|
Business Summary
Dr. Reddys Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products.
View More 
0.12%